Study of Gene Modified WT1 (Wilms' Tumor 1)TCR Therapy in MDS and AML Patients

Conditions:   Myelodysplastic Syndromes (MDS);   Acute Myeloid Leukaemia (AML)Intervention:   Genetic: Gene-modified WT1 TCR-transduced T cells intravenous infusionSponsors:   Cell Therapy Catapult;   Leukaemia Lymphoma Research;   Department of Health, United Kingdom;   University College, LondonRecruiting - verified September 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials